DexCare

📍 Seattle, United States🗓 Founded 2021👥 162 employees💰 Last funded Jun 2023
Incubated at Providence, one of the nation’s largest health systems, DexCare is a data-driven intelligence company focused on making access to healthcare better for everyone. DexCare’s core offering is a software platform, provided exclusively to health systems, that orchestrates digital demand and health system capacity across all lines of care. The platform attracts high-value, commercially-insured consumers by providing a highly discoverable, fully-digitized and unified experience while amplifying health systems’ existing EMR, caregiver and brand investments. The uniqueness of DexCare lies within its intelligent navigation and load balancing across providers, settings, modalities and service lines. DexCare’s data-driven engine allocates, flexes and optimizes resources to best meet both consumer demand and health system business goals. DexCare powers the digital engine of leading health systems across the U.S., including Kaiser Permanente, Houston Methodist, Mass General Brigham and others. DexCare-powered digital experiences attract 30% more new patients, 85% of whom are commercially insured, capture 8x downstream revenue, generate over 20% per patient encounter in cost savings, and deliver net promoter satisfaction greater than 90%.
6
Total investors
6
Early stage
0
Mid stage
0
Late stage
2021
Founded
Investor geography1 country
United States
6
Investor activity2021–2023 · investors recorded per year
2021220234
Recent (last 2y)Earlier
Frequently asked questions
Who invested in DexCare?
DexCare has 6 investors on record on gritt.io, including 6 early-stage backers.
When did DexCare last raise funding?
The most recent investment in DexCare recorded on gritt.io was in June 2023.
When was DexCare founded?
DexCare was founded in 2021.
What industry is DexCare in?
DexCare operates in Software Development. Find similar Software Development investors on gritt.io.
Where is DexCare based?
DexCare is headquartered in Seattle, United States.